These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 31006098

  • 1. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
    Mansha M, Gill A, Thomson PC.
    Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
    [Abstract] [Full Text] [Related]

  • 2. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P, Åkesson A, Hedenfalk I, Malander S, Borgfeldt C.
    PLoS One; 2020 Jun; 15(10):e0240418. PubMed ID: 33075095
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 4. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P, Qin J, Ye H, Li L, Wang X, Zhang J.
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA, Abdou AM.
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [Abstract] [Full Text] [Related]

  • 6. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
    Li W, Wang D.
    Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
    Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M.
    Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X, Ju S.
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis.
    Chen L, Wang X, Shu J, Xu S, Wu Q, Yu Y.
    Int J Gynaecol Obstet; 2019 Nov; 147(2):212-218. PubMed ID: 31469423
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R.
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
    Yanaranop M, Jantarateptewan N, Tiyayon J, Nakrangsee S.
    Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
    [Abstract] [Full Text] [Related]

  • 16. Differential blood count as triage tool in evaluation of pelvic masses.
    Cramer DW, Benjamin Iv WJ, Vitonis AF, Berkowitz R, Goodman A, Matulonis U.
    Int J Gynecol Cancer; 2021 May; 31(5):733-743. PubMed ID: 32487682
    [Abstract] [Full Text] [Related]

  • 17. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F, Pasciuto T, Djokovic D, Di Legge A, Granato V, Moruzzi MC, Mancari R, Zannoni GF, Fischerova D, Franchi D, Scambia G, Testa AC.
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Russell MR, Graham C, D'Amato A, Gentry-Maharaj A, Ryan A, Kalsi JK, Ainley C, Whetton AD, Menon U, Jacobs I, Graham RLJ.
    Br J Cancer; 2017 Aug 22; 117(5):666-674. PubMed ID: 28664912
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.